Titan Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Titan Pharmaceuticals has been growing earnings at an average annual rate of 6.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 44.4% per year.
Key information
6.3%
Earnings growth rate
77.4%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -44.4% |
Return on equity | -83.8% |
Net Margin | -3,026.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Revenue & Expenses BreakdownBeta
How Titan Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -6 | 6 | 0 |
30 Sep 23 | 0 | -6 | 5 | 0 |
30 Jun 23 | 0 | -8 | 6 | 0 |
31 Mar 23 | 0 | -9 | 6 | 0 |
31 Dec 22 | 1 | -10 | 6 | 0 |
30 Sep 22 | 1 | -10 | 6 | 0 |
30 Jun 22 | 1 | -9 | 6 | 0 |
31 Mar 22 | 1 | -9 | 5 | 0 |
31 Dec 21 | 2 | -9 | 5 | 0 |
30 Sep 21 | 3 | -7 | 5 | 0 |
30 Jun 21 | 4 | -7 | 6 | 0 |
31 Mar 21 | 4 | -7 | 6 | 0 |
31 Dec 20 | 5 | -7 | 6 | 0 |
30 Sep 20 | 4 | -2 | 0 | 0 |
30 Jun 20 | 4 | -3 | 2 | 0 |
31 Mar 20 | 3 | -6 | 4 | 0 |
31 Dec 19 | 3 | -7 | 5 | 0 |
30 Sep 19 | 4 | -16 | 12 | 0 |
30 Jun 19 | 4 | -16 | 10 | 0 |
31 Mar 19 | 6 | -11 | 8 | 0 |
31 Dec 18 | 7 | -9 | 7 | 0 |
30 Sep 18 | 5 | -9 | 6 | 0 |
30 Jun 18 | 4 | -11 | 6 | 0 |
31 Mar 18 | 1 | -14 | 5 | 0 |
31 Dec 17 | 0 | -14 | 5 | 0 |
30 Sep 17 | 0 | -13 | 5 | 0 |
30 Jun 17 | 0 | -11 | 5 | 0 |
31 Mar 17 | 15 | 4 | 5 | 0 |
31 Dec 16 | 15 | 5 | 5 | 0 |
30 Sep 16 | 15 | 5 | 5 | 0 |
30 Jun 16 | 15 | 6 | 4 | 0 |
31 Mar 16 | 1 | -8 | 4 | 0 |
31 Dec 15 | 2 | -11 | 4 | 0 |
30 Sep 15 | 3 | -9 | 3 | 0 |
30 Jun 15 | 3 | -7 | 3 | 0 |
31 Mar 15 | 4 | -5 | 3 | 0 |
31 Dec 14 | 4 | -2 | 3 | 0 |
30 Sep 14 | 4 | -2 | 3 | 0 |
30 Jun 14 | 5 | -4 | 3 | 0 |
31 Mar 14 | 6 | 2 | 3 | 0 |
31 Dec 13 | 10 | 10 | 3 | 0 |
30 Sep 13 | 13 | 10 | 4 | 0 |
30 Jun 13 | 12 | 3 | 4 | 0 |
Quality Earnings: TTNP is currently unprofitable.
Growing Profit Margin: TTNP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TTNP is unprofitable, but has reduced losses over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare TTNP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TTNP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: TTNP has a negative Return on Equity (-83.85%), as it is currently unprofitable.